Unternehmen UNT-4634-MAT

Headline

Elthera: Groundbreaking tumor therapy - Novel target combined with state-of-the-art Mode of action

Beschreibung des Unternehmens

Unternehmensgegenstand (Geschäftskonzept, -idee)

Elthera AG is a Swiss Biotech company with the goal of developing an anti-L1CAM antibody based therapy for the treatment of pancreatic and ovarian cancer.

L1 cell adhesion molecule (L1CAM) is an adhesion molecule, which is expressed on many different tumor types, including ovarian, pancreatic, lung, breast, and colon cancer, as well as melanoma, glioblastoma, and others. It has been shown to promote tumor progression by a variety of different mechanisms, e.g. by directly stimulating tumor cell proliferation and the formation of metastases, by promoting angiogenesis in tumors, and by mediating resistance of tumor cells to chemotherapeutic agents.

L1CAM expression is associated with an aggressive tumor type and has been found to be a strong predictor for poor survival, underscoring its key role as a driver of the malignant process.

The Elthera AG product is based on a humanized affinity- and stability-optimized monoclonal antibody (mAb) against L1CAM. The humanized antibody has been used as a building block for the generation of two compounds with different therapeutic approaches, both inducing the targeted killing of cancer cells by two distinct mechanisms.

The first approach is an antibody drug conjugate (ADC). This targeted compound directs the linked cytotoxic agent at high concentrations to the tumor whereas systemic concentrations are low conferring to a favourable safety profile.
The second approach is a bispecific antibody, which recruits and activates cytotoxic T cells, the most efficient killer of the immune system through CD3 binding.

The therapeutic antibody will be developed in conjunction with a diagnostic method to identify the patients with L1CAM positive tumors. Efficient patient selection will reduce the costs of clinical trials and will increase the likelihood of therapeutic success in the treated patients.

Mehr über dieses Unternehmen

Möchten Sie mehr über dieses Unternehmen erfahren (u.a. Markt und Wettbewerb, Management und Mitarbeiter sowie Kapitalbedarf), dann müssen Sie sich hierzu einloggen oder anmelden.

Ihre Ansprechpartner

Für kapitalsuchende Unternehmen und Business Angels / Investoren:
Jochen Oelmann +49 (0)172 - 31 42 52 4
Für Kooperationspartner:
Sebastian Pabst +49 (0)151 - 240 28 101

Gelistete Investoren

Investoren Gesamt: 1116
Business Angels: 769
Family Offices: 52
Venture Capital-/ Private Equity-Gesellschaften: 295

Gelistete Unternehmen

wewave.de ist eine Plattform, auf der Fans personalisierte Videobotschaften von Prominenten buchen können, verbunden mit einem nachhaltigen Charakter. Die Vision ist eine Art "Amazon für Stars".
UNT-8946-MAT
Elthera: Groundbreaking tumor therapy - Novel target combined with state-of-the-art Mode of action
UNT-4634-MAT
Knowhow trifft auf Innovation in einem international boomenden Milliarden-Markt: GamerLegion revolutioniert die Talentförderung der eSport-Generation
UNT-5716-MAT
ODILIA – The deal-driven private marketplace
UNT-9265-MAT
Impact Investing mit erfahrenem Team und Alleinstellungsmerkmalen. Plasticfreeworld ist eine Wachstums-Plattform zur Lösung des globalen Plastikproblems. Großer Markt, große Lösung.
UNT-1055-MAT
Update zu: Einzige SaaS-Lösung für KI-Dienstplanungs- und Ausfallmanagement, 1,3 sek. Reaktionszeit. Revolutioniert Pflege und andere Branchen. Sehr hohes Einsparpotential, mehrfach ausgezeichnet.
UNT-5478-MAT